Temat: "Antineoplastic Agents" - OpacWWW

Starter badań:

Antineoplastics in chemotherapy.

Anticancer drugs used to treat malignancies and cancerous growths.

Salem Press Encyclopedia of Health, 2019. 3p.

Skocz do pozycji: 1 1.

Tytuł :: Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
Autorzy :: Reuss JE; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
Stern D; Yale New Haven Health System, Bridgeport, Connecticut.
Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Ramaswami R; HIV/AIDS Malignancy Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.
Lurain K; HIV/AIDS Malignancy Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.
Chen HX; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Kem R; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Little RF; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Sharon E; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.; Pokaż więcej
Źródło :: JAMA network open [JAMA Netw Open] 2020 Dec 01; Vol. 3 (12), pp. e2027110. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents*/therapeutic use
Patient Selection*
B7-H1 Antigen/*therapeutic use
Clinical Trials as Topic/*methods
HIV Infections/*drug therapy
Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*therapeutic use
Antineoplastic Agents, Immunological ; HIV Infections/blood ; Humans ; Immune Checkpoint Inhibitors ; Program Evaluation
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Amomum subulatum Induces Apoptosis in Tumor Cells and Reduces Tumor Burden in Experimental Animals via Modulating Pro-Inflammatory Cytokines.
Autorzy :: Sudarsanan D; Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer Centre Medical College Campus (Research Centre, University of Kerala), Thiruvananthapuram, Kerala, India.
Suresh Sulekha D; Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer Centre Medical College Campus (Research Centre, University of Kerala), Thiruvananthapuram, Kerala, India.
Chandrasekharan G; Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer Centre Medical College Campus (Research Centre, University of Kerala), Thiruvananthapuram, Kerala, India.; Pokaż więcej
Źródło :: Cancer investigation [Cancer Invest] 2021 Apr; Vol. 39 (4), pp. 333-348. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Amomum*/chemistry
Antineoplastic Agents, Phytogenic/*pharmacology
Apoptosis/*drug effects
Ascites/*drug therapy
Lymphoma, T-Cell/*drug therapy
Plant Extracts/*pharmacology
Animals ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Phytogenic/isolation & purification ; Ascites/blood ; Ascites/pathology ; Cell Line, Tumor ; Cyclophosphamide/pharmacology ; Cytokines/blood ; Inflammation Mediators/blood ; Inflammation Mediators/metabolism ; Lymphoma, T-Cell/blood ; Lymphoma, T-Cell/pathology ; Male ; Mice, Inbred BALB C ; Plant Extracts/isolation & purification ; Signal Transduction ; Tumor Burden/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Chemotherapeutic Agent-Induced Vulvodynia, an Experimental Model.
Autorzy :: Rangappa S; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.
Shankar VK; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.
Jo S; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.
Repka MA; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.
Murthy SN; Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA. .; Institute for Drug Delivery and Biomedical Research, Bangalore, Karnataka, India. .; Pokaż więcej
Źródło :: AAPS PharmSciTech [AAPS PharmSciTech] 2021 Mar 08; Vol. 22 (3), pp. 95. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*adverse effects
Vulvodynia/*chemically induced
Analgesics/therapeutic use ; Animals ; Antineoplastic Agents, Phytogenic/adverse effects ; Disease Models, Animal ; Female ; Gabapentin/therapeutic use ; Neuralgia/chemically induced ; Neuralgia/psychology ; Paclitaxel/adverse effects ; Pain Measurement/drug effects ; Rats ; Rats, Sprague-Dawley
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Autorzy :: Ebrahimi Zade A; Faculty of Industrial Engineering and Systems Management, Amirkabir University of Technology, Tehran, Iran.
Shahabi Haghighi S; Faculty of Industrial Engineering and Systems Management, Amirkabir University of Technology, Tehran, Iran. Electronic address: .
Soltani M; Faculty of Mechanical Engineering, K.N. Toosi University of Technology, Tehran 1969764499, Iran; Advanced Bioengineering Initiative Center, Computational Medicine Center, K. N. Toosi University of Technology, Tehran, Iran; Centre for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON, Canada; Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, Canada.; Pokaż więcej
Źródło :: Computer methods and programs in biomedicine [Comput Methods Programs Biomed] 2020 Sep; Vol. 193, pp. 105443. Date of Electronic Publication: 2020 Mar 19.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents*/therapeutic use
Brain Neoplasms*/drug therapy
Glioblastoma*/drug therapy
Adult ; Antineoplastic Agents, Alkylating/therapeutic use ; Cell Line, Tumor ; Humans ; Temozolomide/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy.
Autorzy :: Aschele C; Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Negru ME; Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Pastorino A; Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Cavanna L; Department of Oncology-Hematology, G. da Saliceto Hospital, Piacenza, Italy.
Zagonel V; Oncology Unit 1, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
Barone-Adesi F; Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.; CRIMEDIM - Research Center in Emergency and Disaster Medicine, Università del Piemonte Orientale, Novara, Italy.
Blasi L; Medical Oncology Unit, Ospedale Civico, Arnas, Palermo.; Pokaż więcej
Źródło :: JAMA oncology [JAMA Oncol] 2021 Feb 01; Vol. 7 (2), pp. 304-306.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*therapeutic use
COVID-19/*epidemiology
Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/epidemiology ; COVID-19/physiopathology ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/epidemiology ; Female ; Hospitalization ; Humans ; Immunotherapy ; Italy/epidemiology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/epidemiology ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasms/epidemiology ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/epidemiology ; SARS-CoV-2
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Autorzy :: Hur J; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13496, Korea.
Ghosh M; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13496, Korea.
Kim TH; Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Park N; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Pandey K; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Cho YB; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Hong SD; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13496, Korea.
Katuwal NB; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13496, Korea.
Kang M; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
An HJ; Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Moon YW; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2021 Jan 27; Vol. 22 (3). Date of Electronic Publication: 2021 Jan 27.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*pharmacology
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Apoptosis/*drug effects
Ataxia Telangiectasia Mutated Proteins/*metabolism
Camptothecin/*analogs & derivatives
Carcinoma, Ovarian Epithelial/*drug therapy
Ovarian Neoplasms/*drug therapy
Pyrimidines/*pharmacology
Sulfoxides/*pharmacology
Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Phytogenic/pharmacology ; Antineoplastic Agents, Phytogenic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/pharmacology ; Camptothecin/therapeutic use ; Carcinoma, Ovarian Epithelial/pathology ; Cell Cycle ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Checkpoint Kinase 1/metabolism ; Drug Synergism ; Female ; G2 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Immunohistochemistry ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Ovarian Neoplasms/pathology ; Phosphorylation ; Pyrimidines/therapeutic use ; Sulfoxides/therapeutic use ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 7 7.

Tytuł :: Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators.
Autorzy :: Wang S; School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
Wang SQ; Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Cancer Institute, Zhengzhou 450008, China.
Teng QX; College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Yang L; Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Lei ZN; College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Yuan XH; School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
Huo JF; School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
Chen XB; Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Cancer Institute, Zhengzhou 450008, China.
Wang M; Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Yu B; School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.
Chen ZS; College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Liu HM; School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou 450001, China.; Pokaż więcej
Źródło :: Journal of medicinal chemistry [J Med Chem] 2020 Dec 24; Vol. 63 (24), pp. 15979-15996. Date of Electronic Publication: 2020 Dec 05.
Typ publikacji :: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Drug Synergism*
Antineoplastic Agents/*chemistry
Antineoplastic Agents/*pharmacology
Colonic Neoplasms/*drug therapy
Drug Resistance, Neoplasm/*drug effects
Pyrimidines/*chemistry
ATP Binding Cassette Transporter, Subfamily B/agonists ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; Animals ; Antineoplastic Agents, Phytogenic/pharmacology ; Apoptosis ; Cell Proliferation ; Colonic Neoplasms/metabolism ; Colonic Neoplasms/pathology ; Drug Resistance, Multiple/drug effects ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Paclitaxel/pharmacology ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissues.
Autorzy :: Noto PB; Experimental Medicine Unit, Oncology R&D, GSK, Collegeville, USA. .
Sikorski TW; Protein Mass Spectrometry, In Vitro/In Vivo Translation, Research, GSK, Collegeville, USA.
Zappacosta F; Discovery Analytical, Medicinal Science and Technology, Research, GSK, Collegeville, USA.
Wagner CD; Discovery Analytical, Medicinal Science and Technology, Research, GSK, Collegeville, USA.
Montes de Oca R; Experimental Medicine Unit, Oncology R&D, GSK, Collegeville, USA.
Szapacs ME; Protein Mass Spectrometry, In Vitro/In Vivo Translation, Research, GSK, Collegeville, USA.
Annan RS; Discovery Analytical, Medicinal Science and Technology, Research, GSK, Collegeville, USA.
Liu Y; Epigenetics, Oncology R&D, GSK, Collegeville, USA.
McHugh CF; Discovery DMPK, In Vitro / In Vivo Translation, Research, GSK, Collegeville, USA.
Mohammad HP; Epigenetics, Oncology R&D, GSK, Collegeville, USA.
Piccoli SP; Experimental Medicine Unit, Oncology R&D, GSK, Collegeville, USA.; Clinical Biomarkers and Diagnostics, Sun Pharmaceutical Advanced Research Center (SPARC), Princeton, USA.
Creasy CL; Epigenetics, Oncology R&D, GSK, Collegeville, USA.; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Dec 17; Vol. 10 (1), pp. 22155. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji :: Journal Article
MeSH Terms :: Biomarkers*
Antineoplastic Agents/*pharmacokinetics
Heterogeneous Nuclear Ribonucleoprotein A1/*metabolism
Protein-Arginine N-Methyltransferases/*antagonists & inhibitors
Repressor Proteins/*antagonists & inhibitors
Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/chemistry ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Agents, Immunological/pharmacology ; Arginine/metabolism ; Cells, Cultured ; Chromatography, Liquid ; Drug Monitoring ; Enzyme Activation ; Enzyme Inhibitors/pharmacokinetics ; Enzyme Inhibitors/therapeutic use ; Gene Expression Regulation, Neoplastic/drug effects ; Heterogeneous Nuclear Ribonucleoprotein A1/blood ; Humans ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/metabolism ; Mass Spectrometry ; Methylation ; Mice ; Molecular Targeted Therapy ; Neoplasms/blood ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Protein-Arginine N-Methyltransferases/genetics ; Repressor Proteins/genetics ; Substrate Specificity
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
Autorzy :: Fischer K; Department of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Al-Sawaf O; Department of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Hallek M; Department of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.; Pokaż więcej
Źródło :: Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2020 Dec 04; Vol. 2020 (1), pp. 357-362.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Antineoplastic Agents/*adverse effects
Bridged Bicyclo Compounds, Heterocyclic/*adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Sulfonamides/*adverse effects
Tumor Lysis Syndrome/*etiology
Tumor Lysis Syndrome/*prevention & control
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Female ; Humans ; Protein Kinase Inhibitors/therapeutic use ; Sulfonamides/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Cytotoxic triterpenoid saponins from the root of Anemone tomentosa (Maxim.) Pei.
Autorzy :: Zhang Y; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Niu X; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Jia Y; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Lv C; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Wang J; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Jia L; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Lu J; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.; Pokaż więcej
Źródło :: Natural product research [Nat Prod Res] 2020 Dec; Vol. 34 (24), pp. 3462-3469. Date of Electronic Publication: 2019 Feb 27.
Typ publikacji :: Journal Article
MeSH Terms :: Anemone/*chemistry
Antineoplastic Agents, Phytogenic/*pharmacology
Triterpenes/*chemistry
Triterpenes/*pharmacology
Antineoplastic Agents/analysis ; Antineoplastic Agents, Phytogenic/chemistry ; Cell Line, Tumor ; Drug Screening Assays, Antitumor ; Humans ; Magnetic Resonance Spectroscopy ; Molecular Structure ; PC-3 Cells ; Plant Extracts/chemistry ; Plant Roots/chemistry ; Saponins/chemistry ; Saponins/pharmacology ; Spectrometry, Mass, Electrospray Ionization
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Autorzy :: Feinberg BA; Cardinal Health Specialty Solutions, Dublin, Ohio.
Zettler ME; Cardinal Health Specialty Solutions, Dublin, Ohio.
Klink AJ; Cardinal Health Specialty Solutions, Dublin, Ohio.
Lee CH; Cardinal Health Specialty Solutions, Dublin, Ohio.
Gajra A; Cardinal Health Specialty Solutions, Dublin, Ohio.
Kish JK; Cardinal Health Specialty Solutions, Dublin, Ohio.; Pokaż więcej
Źródło :: JAMA network open [JAMA Netw Open] 2021 Feb 01; Vol. 4 (2), pp. e2036741. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Response Evaluation Criteria in Solid Tumors*
Antineoplastic Agents, Immunological/*therapeutic use
Breast Neoplasms/*drug therapy
Carcinoma/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Thyroid Neoplasms/*drug therapy
Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/pathology ; Carcinoma/diagnostic imaging ; Carcinoma/secondary ; Clinical Trials as Topic ; Feasibility Studies ; Female ; Humans ; Male ; Melanoma/diagnostic imaging ; Melanoma/secondary ; Molecular Targeted Therapy ; Nivolumab/therapeutic use ; Observer Variation ; Retrospective Studies ; Skin Neoplasms/pathology ; Thyroid Neoplasms/pathology ; Treatment Outcome ; Tumor Burden
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data.
Autorzy :: Park R; Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA.
Lee SA; Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA.
Kim SY; Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA.
de Melo AC; Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Kasi A; Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas, MO, USA.; Pokaż więcej
Źródło :: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2021 Jan; Vol. 60 (1), pp. 13-19. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :: Immunotherapy*
Surgical Procedures, Operative*
Antineoplastic Agents/*therapeutic use
COVID-19/*mortality
Neoplasms/*therapy
Antineoplastic Agents, Immunological/therapeutic use ; COVID-19/complications ; Humans ; Molecular Targeted Therapy ; Neoplasms/complications ; Risk Factors ; SARS-CoV-2
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Autorzy :: Cortes J; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: .
Cescon DW; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
Nowecki Z; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Yusof MM; Pantai Hospital, Kuala Lumpur, Malaysia.
Gallardo C; Arturo Lopez Perez Foundation, Santiago, Chile.
Lipatov O; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russia.
Barrios CH; Oncology Research Unit, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
Holgado E; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan.
Masuda N; National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Otero MT; Oncomedica, Monteria, Colombia.
Gokmen E; Ege University Medical Faculty, Izmir, Turkey.
Loi S; Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
Guo Z; Merck, Kenilworth, NJ, USA.
Zhao J; Merck, Kenilworth, NJ, USA.
Aktan G; Merck, Kenilworth, NJ, USA.
Karantza V; Merck, Kenilworth, NJ, USA.
Schmid P; Barts Cancer Institute, Centre for Experimental Cancer Medicine and Queen Mary University of London, London, UK.; Pokaż więcej
Corporate Authors :: KEYNOTE-355 Investigators
Źródło :: Lancet (London, England) [Lancet] 2020 Dec 05; Vol. 396 (10265), pp. 1817-1828.
Typ publikacji :: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Neoplasm Recurrence, Local/*drug therapy
Triple Negative Breast Neoplasms/*drug therapy
Adult ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B7-H1 Antigen/drug effects ; B7-H1 Antigen/metabolism ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Outcome Assessment, Health Care ; Placebos/administration & dosage ; Progression-Free Survival ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/secondary
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Autorzy :: Chang CY; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.; Center for Drug Evaluation and Safety, University of Florida College of Pharmacy, Gainesville.
Park H; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.; Center for Drug Evaluation and Safety, University of Florida College of Pharmacy, Gainesville.
Malone DC; Department of Pharmacotherapy, The University of Utah College of Pharmacy, Salt Lake City.
Wang CY; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.; Center for Drug Evaluation and Safety, University of Florida College of Pharmacy, Gainesville.
Wilson DL; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.
Yeh YM; National Cheng-Kung University Hospital, Department of Internal Medicine, National Cheng Kung University College of Medicine, Tainan, Taiwan.
Van Boemmel-Wegmann S; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.; Center for Drug Evaluation and Safety, University of Florida College of Pharmacy, Gainesville.
Lo-Ciganic WH; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.; Center for Drug Evaluation and Safety, University of Florida College of Pharmacy, Gainesville.; Pokaż więcej
Źródło :: JAMA network open [JAMA Netw Open] 2020 Mar 02; Vol. 3 (3), pp. e201611. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji :: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :: Antineoplastic Agents, Immunological*/administration & dosage
Antineoplastic Agents, Immunological*/adverse effects
Antineoplastic Agents, Immunological*/therapeutic use
Melanoma*/drug therapy
Melanoma*/mortality
Skin Neoplasms/*drug therapy
Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Randomized Controlled Trials as Topic
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: The landscape of new drugs in extranodal NK/T-cell lymphoma.
Autorzy :: Wang L; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing Tongren Hospital, Beijing 100730, China. Electronic address: .
Li LR; Department of Breast Surgery, Peking Union Medical College Hospital, Beijing 100032, China.
Zhang L; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing 100730, China.
Wang JW; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.; Pokaż więcej
Źródło :: Cancer treatment reviews [Cancer Treat Rev] 2020 Sep; Vol. 89, pp. 102065. Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*pharmacology
Lymphoma, Extranodal NK-T-Cell/*drug therapy
Lymphoma, Extranodal NK-T-Cell/*therapy
Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacology ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacology ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/pharmacology ; Immunotherapy/methods ; Immunotherapy, Adoptive ; Molecular Targeted Therapy/methods ; Small Molecule Libraries/administration & dosage ; Small Molecule Libraries/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Autorzy :: Gougis P; Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France. Electronic address: .
Fenioux C; Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France.
Funck-Brentano C; Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France.
Veyri M; Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, équipe Theravir, France.
Gligorov J; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France; Sorbonne Université, INSERM U-938, CLIP(2) Galilée, Assistance-Publique - Hôpitaux de Paris, Tenon Hospital, Medical Oncology Department, Paris, France.
Solas C; Aix Marseille Univ, APHM, INSERM 1207, IRD 190, UVE, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, F-13005 Marseille, France.
Spano JP; Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France; Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, équipe Theravir, France.; Pokaż więcej
Źródło :: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 1-3. Date of Electronic Publication: 2020 Jun 10.
Typ publikacji :: Letter
MeSH Terms :: Antineoplastic Agents/*adverse effects
Antiviral Agents/*adverse effects
Coronavirus Infections/*drug therapy
Neoplasms/*drug therapy
Pneumonia, Viral/*drug therapy
Amides/adverse effects ; Amides/metabolism ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents, Hormonal/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Betacoronavirus ; COVID-19 ; Chemical and Drug Induced Liver Injury/etiology ; Coronavirus Infections/complications ; Cytochrome P-450 Enzyme System/metabolism ; Drug Combinations ; Drug Interactions ; Histone Deacetylase Inhibitors/adverse effects ; Humans ; Hydroxychloroquine/adverse effects ; Immunosuppression/adverse effects ; Kidney Diseases/chemically induced ; Long QT Syndrome/chemically induced ; Lopinavir/adverse effects ; Neoplasms/complications ; Pandemics ; Pneumonia, Viral/complications ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Proteasome Inhibitors/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Pyrazines/adverse effects ; Pyrazines/metabolism ; Ritonavir/adverse effects ; SARS-CoV-2
SCR Protocol :: COVID-19 drug treatment
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.
Autorzy :: Sweiss K; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.; Cancer Center, University of Illinois, Chicago, IL, USA.
Calip GS; Cancer Center, University of Illinois, Chicago, IL, USA.; Center for Pharmacoepidemiology and Pharmacoeconomic Research, 14681University of Illinois at Chicago, Chicago, IL, USA.
Holden J; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.
Lewkowski P; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.
Mialik I; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.
Johnson J; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.; Cancer Center, University of Illinois, Chicago, IL, USA.
Galvin JP; Cancer Center, University of Illinois, Chicago, IL, USA.; Division of Hematology/Oncology, 14681University of Illinois at Chicago, Chicago, IL, USA.
Rondelli D; Cancer Center, University of Illinois, Chicago, IL, USA.; Division of Hematology/Oncology, 14681University of Illinois at Chicago, Chicago, IL, USA.
Patel P; Cancer Center, University of Illinois, Chicago, IL, USA.; Division of Hematology/Oncology, 14681University of Illinois at Chicago, Chicago, IL, USA.; Pokaż więcej
Źródło :: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Apr; Vol. 27 (3), pp. 579-587. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*administration & dosage
Antineoplastic Agents, Alkylating/*administration & dosage
Melphalan/*administration & dosage
Stem Cell Transplantation/*methods
Vidarabine/*analogs & derivatives
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/therapeutic use ; Creatinine/metabolism ; Diarrhea/epidemiology ; Female ; Hemoglobins/metabolism ; Humans ; Male ; Melphalan/adverse effects ; Melphalan/therapeutic use ; Middle Aged ; Neoplasms/drug therapy ; Predictive Value of Tests ; Recurrence ; Retrospective Studies ; Survival Analysis ; Transplantation Conditioning ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.
Autorzy :: Yang N; Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University.
Zhang PL; Internal Medicine Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Liu ZJ; Internal Medicine Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Oct 30; Vol. 99 (44), pp. e22933.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*radiotherapy
Antineoplastic Agents, Immunological/*therapeutic use
Bevacizumab/*therapeutic use
Immunotherapy/*methods
Iodine Radioisotopes/*therapeutic use
Lung Neoplasms/*radiotherapy
Adenocarcinoma of Lung/diagnostic imaging ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/pathology ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Combined Modality Therapy ; Disease Progression ; Humans ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Tomography, X-Ray Computed
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Targeted therapy for metastatic renal cell carcinoma.
Autorzy :: Hofmann F; Department of Urology, Sunderby Sjukhus, Umeå University, Luleå, Sweden.
Hwang EC; Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South.
Lam TB; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
Bex A; Department of Urology and UCL Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, London, UK.
Yuan Y; Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Canada.
Marconi LS; Department of Urology and Renal Transplantation, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
Ljungberg B; Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.; Pokaż więcej
Źródło :: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Oct 14; Vol. 10. Cochrane AN: CD012796. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji :: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :: Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Axitinib/adverse effects ; Axitinib/therapeutic use ; Bevacizumab/adverse effects ; Bevacizumab/therapeutic use ; Bias ; Carcinoma, Renal Cell/mortality ; Everolimus/adverse effects ; Everolimus/therapeutic use ; Humans ; Ipilimumab/adverse effects ; Ipilimumab/therapeutic use ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Phenylurea Compounds/adverse effects ; Phenylurea Compounds/therapeutic use ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Quality of Life ; Quinolines/adverse effects ; Quinolines/therapeutic use ; Randomized Controlled Trials as Topic ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Sirolimus/adverse effects ; Sirolimus/analogs & derivatives ; Sirolimus/therapeutic use ; Sorafenib/adverse effects ; Sorafenib/therapeutic use ; Sulfonamides/adverse effects ; Sulfonamides/therapeutic use ; Sunitinib/adverse effects ; Sunitinib/therapeutic use
SCR Disease Name :: Clear-cell metastatic renal cell carcinoma
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents.
Autorzy :: Park KC; Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, New South Wales 2006, Australia.
Richardson DR; Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, New South Wales 2006, Australia,; Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Centre for Cancer Cell Biology, Griffith University, Griffith Institute of Drug Discovery, Nathan, Brisbane, Queensland, Australia. Electronic address: .; Pokaż więcej
Źródło :: Biochimica et biophysica acta. General subjects [Biochim Biophys Acta Gen Subj] 2020 Oct; Vol. 1864 (10), pp. 129650. Date of Electronic Publication: 2020 Jun 06.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Antineoplastic Agents/*pharmacology
Neoplasms/*drug therapy
Neoplasms/*metabolism
Proteolysis/*drug effects
Proto-Oncogene Proteins c-met/*metabolism
Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents, Immunological/chemistry ; Antineoplastic Agents, Immunological/pharmacology ; Disease Progression ; Drug Discovery ; Humans ; Molecular Targeted Therapy ; Neoplasms/genetics ; Proto-Oncogene Proteins c-met/analysis ; Proto-Oncogene Proteins c-met/genetics ; Thiosemicarbazones/chemistry ; Thiosemicarbazones/pharmacology
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antineoplastic Agents"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Starter badań:

Antineoplastics in chemotherapy.